ArticlemAbs
TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Validation and quantification of peptide antigens presented on MHCs using SureQuant.Nature protocols · 2025Review
- Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein.BMC biology · 2024Article
- PBMC-engrafted humanized mice models for evaluating immune-related and anticancer drug delivery systems.Frontiers in molecular biosciences · 2024Review
- Review
- MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.Journal for immunotherapy of cancer · 2022Article
- TCR mimic compounds for pHLA targeting with high potency modalities in oncology.Frontiers in oncology · 2022Review
- 1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs.Immuno-oncology technology · 2021Review
- Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors.Nanoscale · 2021Article
- Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy.Human vaccines & immunotherapeutics · 2021Review
- Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Bispecific antibodies targeting mutantScience immunology · 2021Article
- Affinity Maturation of a T-Cell Receptor-Like Antibody Specific for a Cytomegalovirus pp65-Derived Peptide Presented by HLA-A*02:01.International journal of molecular sciences · 2021Article
- Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen.Nature communications · 2019Article
- The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.International journal of molecular sciences · 2019Article
- Opportunities and Challenges for Antibodies against Intracellular Antigens.Theranostics · 2019Review
- Expression and characterization of soluble epitope-defined major histocompatibility complex (MHC) from stable eukaryotic cell lines.Journal of immunological methods · 2019Article
- Self-Induced Back-Action Actuated Nanopore Electrophoresis (SANE) Sensor for Label-Free Detection of Cancer Immunotherapy-Relevant Antibody-Ligand Interactions.Methods in molecular biology (Clifton, N.J.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The currently marketed antibody-drug conjugates (ADC) destabilize microtubule assembly in cancer cells and initiate apoptosis in patients. However, few tumor antigens (TA) are expressed at high densities on cancer lesions, potentially minimizing the therapeutic index of current ADC regimens. The peptide/human leukocyte antigen (HLA) complex can be specifically targeted by therapeutic antibodies (designated T cell receptor [TCR]-like antibodies) and adequately distinguish malignant cells, but has not been the focus of ADC development. We analyzed the killing potential of TCR-like ADCs when cross-linked to the DNA alkylating compound duocarmycin. Our data comprise proof-of-principle results that TCR-like ADCs mediate potent tumor cytotoxicity, particularly under common scenarios of low TA/HLA density, and support their continued development alongside agents that disrupt DNA replication. Additionally, TCR-like antibody ligand binding appears to play an important role in ADC functionality and should be addressed during therapy development to avoid binding patterns that negate ADC killing efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.